Systematic Review and Meta-Analysis Evaluates GLP-1 Receptor Agonists for MASH with Fibrosis

Metabolic dysfunction-associated steatohepatitis (MASH) represents a significant and escalating global health challenge, serving as a primary risk factor for progressive hepatic fibrosis and ultimately cirrhosis. Current therapeutic options for MASH remain limited, leaving a critical unmet clinical need for effective interventions that can halt or reverse liver damage. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as promising candidates, with ongoing investigations into their specific role and efficacy in treating patients with MASH who also present with fibrosis. A comprehensive understanding of their collective therapeutic effects is essential to guide clinical practice.

This research involved a systematic review and meta-analysis designed to comprehensively evaluate the therapeutic effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs). The study's objective was to synthesize existing clinical evidence regarding the use of these agents in patients diagnosed with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). The methodology focused on aggregating and analyzing data from various studies to provide a robust overview of GLP-1RA efficacy in this specific patient population.

The provided abstract outlines the objective and background for a systematic review and meta-analysis but does not present any specific findings, numerical results, or statistical outcomes from the analysis itself. Consequently, this summary cannot report on percentages, p-values, fold-changes, or other quantitative data that would typically emerge from such a study. The meta-analysis was designed to evaluate the therapeutic effects of GLP-1RAs in patients with MASLD and MASH, particularly those with fibrosis, but the results of this evaluation are not detailed in the available text. Therefore, no concrete conclusions regarding the efficacy or safety profile of GLP-1RAs based on the aggregated data can be drawn from this abstract alone. The study's intent was to provide a comprehensive overview, but the outcomes of that synthesis are not yet disclosed.